Ratha Mahendran

Dr. Ratha Mahendran

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2010 in Cancer Science
Verified
Journal Article
Closed access
PDF file
SSShih Wee Seow
Shih Wee Seow
SCShirong Cai
Shirong Cai
JRJuwita Norasmara Rahmat
Juwita Norasmara Rahmat
BBBoon Huat Bay
Boon Huat Bay
YLYuan Kun Lee
Yuan Kun Lee
RMRatha Mahendran
Ratha Mahendran

1 January 2016 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
SCShirong Cai
Shirong Cai
MKMatheswaran Kandasamy
Matheswaran Kandasamy
JRJuwita Norasmara Rahmat
Juwita Norasmara Rahmat
TMTham Sin Mun
Tham Sin Mun
BBBoon Huat Bay
Boon Huat Bay
RMRatha Mahendran
Ratha Mahendran
This study evaluates the ability ofLactobacillus rhamnosusGG (LGG) to activate DC and neutrophils and modulate T cell activation and the impact of bacterial dose on these responses. Murine bone marrow derived DC or neutrophils were stimulated with LGG at ratios of 5 : 1, 10 : 1, and 100 : 1 (LGG : cells) and DC maturation (CD40, CD80, CD86, CD83, and MHC class II) and cytokine production (IL-10, TNF-α, and IL-12p70) were examined after 2 h and 18 h coculture and compared to the ability of BCG (the present immunotherapeutic agent for bladder cancer) to stimulate these cells. A 2 h exposure to 100 : 1 (high dose) or an 18 h exposure to 5 : 1 or 10 : 1 (low dose), LGG : cells, induced the highest production of IL-12 and upregulation of CD40, CD80, CD86, and MHC II on DC. In DCs stimulated with LGG activated neutrophils IL-12 production decreased with increasing dose. LGG induced 10-fold greater IL-12 production than BCG. T cell IFNγand IL-2 production was significantly greater when stimulated with DC activated with low dose LGG. In conclusion, DC or DC activated with neutrophils exposed to low dose LGG induced greater Th1 polarization in T cells and this could potentially exert stronger antitumor effects. Thus the dose of LGG used for immunotherapy could determine treatment efficacy.

24 January 2008 in Immunology
Verified
Journal Article
Open access
PDF file
SSShih Wee Seow
Shih Wee Seow
JRJuwita Norasmara Rahmat
Juwita Norasmara Rahmat
BBBoon Huat Bay
Boon Huat Bay
YLYuan Kun Lee
Yuan Kun Lee
RMRatha Mahendran
Ratha Mahendran
Summary: Mycobacterium bovis, bacillus Calmette–Guérin (BCG) is the current gold standard for bladder cancer therapy. In this study a profile of the gene expression changes that occur after BCG instillation in the bladders of healthy mice was produced and compared to the type of immune cells recruited into the bladder. A similar comparison was made for Lactobacillus rhamnosus strain GG (LGG) instillations in healthy mice to determine its potential in the immunotherapy of bladder cancer. Mice were given six weekly instillations and were killed after the fourth, fifth and sixth instillations of BCG or LGG. Their bladders were harvested for chemokine/cytokine messenger RNA analysis using an array as well as semi‐quantitative reverse transcription–polymerase chain reaction. In a second set of mice both the bladder and draining lymph nodes were harvested for the analysis of immune cells. BCG significantly upregulated genes for T helper type 1 (Th1) chemokines: Cxcl2, Cxcl9, Cxcl10, Xcl1; and increased the expression of Th1/Th2 chemokines: RANTES, Ccl6 and Ccl7; Th1 polarizing cytokines: Il1β and Tnfa; and Fcγr1 and iNOS as early as after four weekly instillations. Most of these genes remained highly expressed after 6 weeks. In contrast, LGG transiently induced Cxcl10, Il16, Fcεr1 and Il1r2. Despite these findings, LGG instillation induced the recruitment of natural killer cells into the bladder and draining lymph nodes, as was observed for BCG instillation.

28 April 2004 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
MTMaung-Maung Thwin
Maung-Maung Thwin
Eleni K. DouniEleni K. Douni
Eleni K. Douni
Vassilis AidinisVassilis Aidinis
Vassilis Aidinis
GKGeorge Kollias
George Kollias
KKKyoko Kodama
Kyoko Kodama
PGPonnampalam Gopalakrishnakone
Ponnampalam Gopalakrishnakone
We evaluated the therapeutic effect of secretory phospholipase A2 (sPLA2)-inhibitory peptide at a cellular level on joint erosion, cartilage destruction, and synovitis in the human tumor necrosis factor (TNF) transgenic mouse model of arthritis. Tg197 mice (N = 18) or wild-type (N = 10) mice at 4 weeks of age were given intraperitoneal doses (7.5 mg/kg) of a selective sPLA2 inhibitory peptide, P-NT.II, or a scrambled P-NT.II (negative control), three times a week for 4 weeks. Untreated Tg197 mice (N = 10) were included as controls. Pathogenesis was monitored weekly for 4 weeks by use of an arthritis score and histologic examinations. Histopathologic analysis revealed a significant reduction after P-NT.II treatment in synovitis, bone erosion, and cartilage destruction in particular. Conspicuous ultrastructural alterations seen in articular chondrocytes (vacuolated cytoplasm and loss of nuclei) and synoviocytes (disintegrating nuclei and vacuoles, synovial adhesions) of untreated or scrambled-P-NT.II-treated Tg197 mice were absent in the P-NT.II-treated Tg197 group. Histologic scoring and ultrastructural evidence suggest that the chondrocyte appears to be the target cell mainly protected by the peptide during arthritis progression in the TNF transgenic mouse model. This is the first time ultrastructural evaluation of this model has been presented. High levels of circulating sPLA2 detected in untreated Tg197 mice at age 8 weeks of age were reduced to basal levels by the peptide treatment. Attenuation of lipopolysaccharide- and TNF-induced release of prostaglandin E2 from cultured macrophage cells by P-NT.II suggests that the peptide may influence the prostaglandin-mediated inflammatory response in rheumatoid arthritis by limiting the bioavailability of arachidonic acid through sPLA2 inhibition.

15 June 2011 in Cellular Immunology
Verified
Journal Article
Closed access
MKMatheswaran Kandasamy
Matheswaran Kandasamy
BBBoon-Huat Bay
Boon-Huat Bay
YLYuan-Kun Lee
Yuan-Kun Lee
RMRatha Mahendran
Ratha Mahendran

Verified
Journal Article
Open access
PDF file
MPMugdha Patwardhan
Mugdha Patwardhan
RMRatha Mahendran
Ratha Mahendran
The tumor microenvironment (TME) is complex and involves many different cell types that seemingly work together in helping cancer cells evade immune monitoring and survive therapy. The advent of single-cell sequencing has greatly increased our knowledge of the cell types present in the tumor microenvironment and their role in the developing cancer. This, coupled with clinical data showing that cancer development and the response to therapy may be influenced by drugs that indirectly influence the tumor environment, highlights the need to better understand how the cells present in the TME work together. This review looks at the different cell types (cancer cells, cancer stem cells, endothelial cells, pericytes, adipose cells, cancer-associated fibroblasts, and neuronal cells) in the bladder tumor microenvironment. Their impact on immune activation and on shaping the microenvironment are discussed as well as the effects of hypertensive drugs and anesthetics on bladder cancer.